TransCode Therapeutics (RNAZ) Q4 2025 earnings summary

Executive summary

• Completed acquisition of Polynoma, adding Seviprotimut-L, a Phase 2 cancer vaccine candidate, to the pipeline and expanding immuno-oncology capabilities.

• Lead candidate TTX-MC138 advanced through Phase 1a clinical trial, showing safety and positive pharmacodynamic effects, with Phase 2a trial planned for 2026.

• Entered exclusive license with Unleash Immuno Oncolytics for three preclinical oncolytic virus candidates, issuing Series C Preferred Stock as consideration.

• Raised $25 million through Series B Preferred Stock and secured a $14 million Standby Equity Purchase Agreement with Yorkville for future funding.

Financial highlights

• Net loss for 2025 was $34.7 million, up from $16.8 million in 2024, driven by increased R&D and acquisition-related costs.

• Cash balance at year-end 2025 was $17.8 million, with $31.5 million raised from equity financings during the year.

• Accumulated deficit reached $97.9 million as of December 31, 2025.

• Research and development expenses rose to $13.4 million, and general and administrative expenses increased to $14.6 million, including $8.8 million in acquisition-related transaction costs.

• Auditor issued a going concern opinion due to recurring losses and limited cash runway.

Outlook and guidance

• Cash on hand expected to fund operations through year-end 2026; additional capital will be required for further development and commercialization.

• Phase 2a clinical trial for TTX-MC138 planned to begin in 2026, with continued development of Seviprotimut-L and Unleash oncolytic virus candidates.

• Company anticipates increased R&D and operating expenses as pipeline advances.